Is it time to reconsider prophylactic antimicrobial use for hematopoietic stem cell transplantation? a narrative review of antimicrobials in stem cell transplantation.
Dilshad JahanEd PeileMd Arif SheikhSalequl IslamSharlene ParasnathParas SharmaKatia IskandarSameer DhingraJaykaran CharanTimothy Craig HardcastleNandeeta SamadTajkera Sultana ChowdhurySiddhartha DuttaMainul HaquePublished in: Expert review of anti-infective therapy (2021)
Measures to control infection and its transmission remain significant HSCT management policy and planning issues. Transplant centers need to consider carefully prophylactic use of antimicrobials for neutropenic patients. The judicious use of appropriate antimicrobials remains a crucial part of the treatment protocol. However, antimicrobials' adverse effects cause microbiome diversity and dysbiosis and have been shown to increase morbidity and mortality.
Keyphrases
- stem cell transplantation
- end stage renal disease
- high dose
- ejection fraction
- newly diagnosed
- chronic kidney disease
- healthcare
- randomized controlled trial
- acute myeloid leukemia
- staphylococcus aureus
- mental health
- peritoneal dialysis
- low dose
- patient reported outcomes
- replacement therapy
- smoking cessation
- combination therapy